[Opioids in Musculoskeletal Pain]

Overview

Journal Z Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2008 Nov 18

PMID 19011881

Authors

L Siegel

M Pierer

C Stein

C Baerwald

Affiliations

Soon will be listed here.

Abstract

Opioids are the most potent analgesics available and are well established for the treatment of severe acute, surgical and cancer pain. Due to their high effectiveness, their use in chronic non-cancer pain (CNCP) is being propagated. However, the use of opioids is still controversial due to their side effects, such as tolerance, addiction or withdrawal, and administrative difficulties associated with their prescription. Chronic rheumatic diseases, in particular low back pain and arthritis, are the leading causes of CNCP. The present article provides a brief overview of the role of opioids in chronic rheumatic diseases, pointing out that a national guideline for opioid use in CNCP is expected at the end of 2008. Furthermore, the peripheral effects of opioids on pain and inflammation in rheumatic diseases will be outlined.

References

Furlan A, Sandoval J, Mailis-Gagnon A, Tunks E . Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ. 2006; 174(11):1589-94. PMC: 1459894. DOI: 10.1503/cmaj.051528. View

Zollner C, Mousa S, Fischer O, Rittner H, Shaqura M, Brack A . Chronic morphine use does not induce peripheral tolerance in a rat model of inflammatory pain. J Clin Invest. 2008; 118(3):1065-73. PMC: 2214843. DOI: 10.1172/JCI25911. View

Rittner H, Labuz D, Richter J, Brack A, Schafer M, Stein C . CXCR1/2 ligands induce p38 MAPK-dependent translocation and release of opioid peptides from primary granules in vitro and in vivo. Brain Behav Immun. 2007; 21(8):1021-32. DOI: 10.1016/j.bbi.2007.05.002. View

Avouac J, Gossec L, Dougados M . Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2007; 15(8):957-65. DOI: 10.1016/j.joca.2007.02.006. View

Kalso E, Smith L, McQuay H, Moore A . No pain, no gain: clinical excellence and scientific rigour--lessons learned from IA morphine. Pain. 2002; 98(3):269-275. DOI: 10.1016/S0304-3959(02)00019-2. View

Trescot A, Glaser S, Hansen H, Benyamin R, Patel S, Manchikanti L . Effectiveness of opioids in the treatment of chronic non-cancer pain. Pain Physician. 2008; 11(2 Suppl):S181-200. View

Rittner H, Lux C, Labuz D, Mousa S, Schafer M, Stein C . Neurokinin-1 receptor antagonists inhibit the recruitment of opioid-containing leukocytes and impair peripheral antinociception. Anesthesiology. 2007; 107(6):1009-17. DOI: 10.1097/01.anes.0000291454.90754.de. View

Tegeder I, Geisslinger G . Opioids as modulators of cell death and survival--unraveling mechanisms and revealing new indications. Pharmacol Rev. 2004; 56(3):351-69. DOI: 10.1124/pr.56.3.2. View

Eriksen J, Jensen M, Sjogren P, Ekholm O, Rasmussen N . Epidemiology of chronic non-malignant pain in Denmark. Pain. 2003; 106(3):221-228. DOI: 10.1016/S0304-3959(03)00225-2. View

10.

Zhang W, Moskowitz R, Nuki G, Abramson S, Altman R, Arden N . OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008; 16(2):137-62. DOI: 10.1016/j.joca.2007.12.013. View

11.

Hutchinson K, Moreland A, de C Williams A, Weinman J, Horne R . Exploring beliefs and practice of opioid prescribing for persistent non-cancer pain by general practitioners. Eur J Pain. 2006; 11(1):93-8. DOI: 10.1016/j.ejpain.2006.01.003. View

12.

Baerwald C, Burmester G, Krause A . Interactions of autonomic nervous, neuroendocrine, and immune systems in rheumatoid arthritis. Rheum Dis Clin North Am. 2000; 26(4):841-57. DOI: 10.1016/s0889-857x(05)70172-1. View

13.

Stein C, Schafer M, Machelska H . Attacking pain at its source: new perspectives on opioids. Nat Med. 2003; 9(8):1003-8. DOI: 10.1038/nm908. View

14.

Cunha F, Ferreira S . Peripheral hyperalgesic cytokines. Adv Exp Med Biol. 2003; 521:22-39. View

15.

Katz W . Opioids for nonmalignant pain. Rheum Dis Clin North Am. 2008; 34(2):387-413. DOI: 10.1016/j.rdc.2008.04.004. View

16.

Elliott A, Smith B, Penny K, Smith W, Chambers W . The epidemiology of chronic pain in the community. Lancet. 1999; 354(9186):1248-52. DOI: 10.1016/s0140-6736(99)03057-3. View

17.

Berliner M, Giesecke T, Bornhovd K . Impact of transdermal fentanyl on quality of life in rheumatoid arthritis. Clin J Pain. 2007; 23(6):530-4. DOI: 10.1097/AJP.0b013e318074c9b1. View

18.

Bergman S . Management of musculoskeletal pain. Best Pract Res Clin Rheumatol. 2007; 21(1):153-66. DOI: 10.1016/j.berh.2006.10.001. View

19.

Katz W, Rothenberg R . Section 4: treating the patient in pain. J Clin Rheumatol. 2005; 11(2 Suppl):S16-27, discussion S27-8. DOI: 10.1097/01.rhu.0000158685.01291.04. View

20.

Machelska H, Schopohl J, Mousa S, Labuz D, Schafer M, Stein C . Different mechanisms of intrinsic pain inhibition in early and late inflammation. J Neuroimmunol. 2003; 141(1-2):30-9. DOI: 10.1016/s0165-5728(03)00213-3. View